Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Delivery
Bicycle, Ionis sign oligonucleotide delivery pact
by Michael McCoy
July 18, 2021
| A version of this story appeared in
Volume 99, Issue 26
Ionis Pharmaceuticals will pay Bicycle Therapeutics $45 million to license the firm’s bicyclic peptide technology. Bicycle is developing the synthetic short peptides as oncology treatments. But Ionis will use them to deliver oligonucleotide therapeutics to tissue, taking advantage of the high affinity for the transferrin receptor of some of Bicycle’s peptides. Bicycle will retain rights to use the peptides for all nonoligonucleotide delivery applications.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X